[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 52 of about 52
1. Bradshaw MJ, Folpe AL, Croghan GA: Perivascular epithelioid cell neoplasm of the uterine cervix: an unusual tumor in an unusual location. Rare Tumors; 2010;2(4):e56

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perivascular epithelioid cell neoplasm of the uterine cervix: an unusual tumor in an unusual location.
  • A 46-year-old woman presented for a second opinion regarding a 3-4 cm mass of the uterine cervix.
  • A prior biopsy had been interpreted as a malignant melanoma of the cervix, resulting in a radical hysterectomy with bilateral salpingooophorectomy.
  • This was to be followed by external beam irradiation and immunotherapy; however, given the rarity of this diagnosis, the patient sought a second opinion at our institution.
  • Further review of the pathological material from the hysterectomy revealed a morphologically benign perivascular epithelioid cell neoplasm rather than a malignant melanoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2005 Dec;29(12):1558-75 [16327428.001]
  • [Cites] Pathology. 1991 Jul;23(3):185-8 [1664078.001]
  • [Cites] J Cutan Pathol. 2008 Nov;35(11):1014-9 [18547346.001]
  • [Cites] Hum Pathol. 2010 Jan;41(1):1-15 [19604538.001]
  • [Cites] Surg Today. 2009;39(10):916-21 [19784736.001]
  • [Cites] J Obstet Gynaecol. 2009 Oct;29(7):676-7 [19757288.001]
  • [Cites] J Clin Oncol. 2010 Feb 10;28(5):835-40 [20048174.001]
  • [Cites] J Pediatr Hematol Oncol. 2010 May;32(4):e136-8 [20051914.001]
  • [Cites] World J Gastroenterol. 2010 Jan 28;16(4):522-5 [20101783.001]
  • [Cites] Hum Pathol. 2010 May;41(5):768-72 [20236689.001]
  • [Cites] Semin Diagn Pathol. 1998 Feb;15(1):21-40 [9503504.001]
  • [Cites] Arch Pathol Lab Med. 2009 Dec;133(12):1981-4 [19961256.001]
  • (PMID = 21234248.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC3019591
  • [Keywords] NOTNLM ; gynecological neoplasms. / immunohistochemistry / melanoma / perivascular epithelioid cell neoplasm
  •  go-up   go-down


2. Duggal R, Nijhawan R, Aggarwal N, Sikka P: Mullerian adenosarcoma (heterologous) of the cervix with sarcomatous overgrowth: a case report with review of literature. J Gynecol Oncol; 2010 Jun;21(2):125-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mullerian adenosarcoma (heterologous) of the cervix with sarcomatous overgrowth: a case report with review of literature.
  • Mullerian adenosarcoma is a rare biphasic malignant neoplasm of the cervix characterized by an admixture of benign epithelial elements and a malignant sarcomatous stromal component, which may be either homologous or heterologous.
  • In this report we present a case of MASO of uterine cervix with heterologous elements in a 15-year-old unmarried girl presenting with foul smelling menstrual bleeding and passage of fleshy masses.
  • Because MASO with heterologous elements seems to appear at the earliest stages of reproductive lifespan in women, and have an uncertain malignant potential, gynecologists and pathologists should be aware and think about the possibility of this tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1990 Apr;21(4):363-81 [2156771.001]
  • [Cites] Am J Surg Pathol. 1989 Jan;13(1):28-38 [2535774.001]
  • [Cites] Cancer. 1974 Oct;34(4):1138-49 [4371193.001]
  • [Cites] J Clin Pathol. 2008 Sep;61(9):1041-4 [18552169.001]
  • [Cites] Gynecol Oncol. 2007 Apr;105(1):256-60 [17292949.001]
  • [Cites] Ups J Med Sci. 2007;112(1):67-72 [17578809.001]
  • [Cites] Int J Gynecol Cancer. 2004 Sep-Oct;14(5):1024-9 [15361219.001]
  • (PMID = 20613904.001).
  • [ISSN] 2005-0399
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2895712
  • [Keywords] NOTNLM ; Heterologous / Mullerian adenosarcoma / Sarcomatous overgrowth / Uterine cervix
  •  go-up   go-down


3. Missaoui N, Hmissa S, Sankaranarayanan R, Deodhar K, Nene B, Budukh A, Malvi S, Chinoy R, Kelkar R, Kane S, Chauhan M, Kothai A, Kahate S, Fontanière B, Frappart L: [p16INK4A overexpression is a useful marker for uterine cervix lesions]. Ann Biol Clin (Paris); 2010 Jul-Aug;68(4):409-14
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [p16INK4A overexpression is a useful marker for uterine cervix lesions].
  • [Transliterated title] La surexpression de p16 INK4A est un marqueur utile des lésions du col utérin.
  • The histological criteria of uterine cervix lesions are well known.
  • Therefore, the aim of our study was to evaluate the utility of p16INK4A overexpression as a surrogate biomarker of precancerous lesions of the uterine cervix.
  • A retrospective study was carried out by the International Center for Research on Cancer, Lyon, on 79 uterine cervix lesions.
  • Specimens included 4 normal tissue samples, 24 benign lesions, 9 low-grade precancerous lesions (CIN1), 40 high-grade precancerous lesions (CIN2-3) and 2 squamous cell carcinomas.
  • No p16INK4A expression was detected in normal tissues and benign lesions of the uterine cervix. p16INK4A immunolabeling was weak in CIN1 cases (77.8%).
  • In conclusion, p16INK4A overexpression should be regarded as a surrogate biomarker of precancerous lesions of the uterine cervix. p16INK4A overexpression is useful in reducing the variability during evaluation of suspicious biopsies of the uterine cervix.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / genetics. Precancerous Conditions / genetics. Uterine Cervical Diseases / genetics. Uterine Cervical Neoplasms / genetics
  • [MeSH-minor] Female. Gene Expression Regulation. Gene Expression Regulation, Neoplastic. Genes, p16. Genetic Markers. Humans. Neoplasm Staging. Papillomaviridae / isolation & purification. Retrospective Studies. Risk Factors


Advertisement
4. Haberal A, Cil AP, Gunes M, Cavusoglu D: Papillary adenofibroma of the cervix: a case report. Ultrasound Obstet Gynecol; 2005 Aug;26(2):186-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary adenofibroma of the cervix: a case report.
  • Adenofibroma is an extremely rare benign biphasic neoplasm that is classified into the mixed epithelial and mesenchymal tumor group.
  • It typically affects the endometrium, but may occur in the cervix or in an extrauterine location.
  • Preoperative diagnosis of this tumor is usually difficult.
  • We describe the case of a 55-year-old woman with papillary cervical adenofibroma, which appeared as a cervical mass containing multiple cystic components on transvaginal ultrasound.
  • This lesion appears to be clinically and histologically benign but must be differentiated from malignant lesions of the uterus, particularly from adenosarcoma, which can be suggestive of adenofibroma.
  • Accurate diagnosis of these benign tumors permits appropriate counseling of patients.
  • [MeSH-major] Adenofibroma / ultrasonography. Uterine Cervical Neoplasms / ultrasonography

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 ISUOG. Published by John Wiley & Sons, Ltd.
  • (PMID = 16041681.001).
  • [ISSN] 0960-7692
  • [Journal-full-title] Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • [ISO-abbreviation] Ultrasound Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Hollowell ML, Goulart RA, Gang DL, Otis CN, Prior J, Sachs BF, Pantanowitz L: Cytologic features of müllerian papilloma of the cervix: mimic of malignancy. Diagn Cytopathol; 2007 Sep;35(9):607-11
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytologic features of müllerian papilloma of the cervix: mimic of malignancy.
  • Müllerian papilloma is a rare benign tumor of the cervix and/or vagina that occurs predominantly in young children.
  • The cytologic features of benign müllerian papilloma have never been described.
  • We report for the first time, to our knowledge, the cytologic findings of a benign müllerian papilloma from the vaginal fluid specimen of a 15-mo-old girl using touch prep, ThinPrep, and cell block preparations.
  • The deceptive cytologic features of a cellular specimen with complex papillary fronds composed of overlapping and crowded small hyperchromatic cells, with a high nuclear:cytoplasmic ratio, and feathering in this case resembled a malignant neoplasm.
  • The clinical findings and cytomorphology of a benign müllerian papilloma can mimic those of malignant lesions of the female lower genital tract such as sarcoma botryoides and adenocarcinoma.
  • An awareness of this entity and its potential to mimic these more aggressive neoplasms is essential for accurate diagnosis and to avoid over-treatment.
  • [MeSH-major] Papilloma / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Diagnosis, Differential. Female. Humans. Infant. Rhabdomyosarcoma, Embryonal / diagnosis. Rhabdomyosarcoma, Embryonal / pathology


6. Fadare O, Yi X, Liang SX, Ma Y, Zheng W: Variations of mitotic index in normal and dysplastic squamous epithelium of the uterine cervix as a function of endometrial maturation. Mod Pathol; 2007 Sep;20(9):1000-8
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variations of mitotic index in normal and dysplastic squamous epithelium of the uterine cervix as a function of endometrial maturation.
  • Cervical intraepithelial neoplasia is a premalignant (dysplastic) lesion that is characterized by abnormal cellular proliferation, maturation and nuclear atypia.
  • In this study, we evaluated the total mitotic indices of the cervical epithelia in hysterectomy specimens from patients with and without dysplastic lesions and investigated a possible relationship between mitotic index and hormonal status, using the endometrial maturation phase as a surrogate indicator of the latter.
  • Two hundred seventy-four cervices from hysterectomy specimens (135 cases without dysplasia, 33, 35 and 71 cases with grades 1, 2 and 3 cervical intraepithelial neoplasia, respectively) were analyzed.
  • A cervical mitotic index (total mitotic figures/10 high-power fields in the most proliferative area) was determined for each case.
  • For all three dysplasia grades, cases in the proliferative endometrium group always had a higher average mitotic index than those in the secretory and atrophic endometrium groups; this observation also held true for the benign cases.
  • Notably, the average mitotic index for our cervical intraepithelial neoplasia 1 cases with late proliferative endometrium was higher than our cervical intraepithelial neoplasia 2 cases with secretory and atrophic endometrium.
  • It is concluded that hormonal status, as reflected in endometrial maturation, can significantly affect the mitotic index of dysplastic squamous epithelium of the uterine cervix.
  • Our findings confirm that the pathologic grading of dysplasia, especially in equivocal cases such as in metaplastic squamous epithelium, should not be solely dependent on the finding mitoses in the cervical squamous epithelium.
  • [MeSH-major] Cell Proliferation. Cervical Intraepithelial Neoplasia / diagnosis. Cervix Uteri / pathology. Endometrium / pathology. Epithelial Cells / pathology. Menstrual Cycle. Mitotic Index. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Metaplasia. Middle Aged. Neoplasm Staging. Retrospective Studies


7. Rabban JT, McAlhany S, Lerwill MF, Grenert JP, Zaloudek CJ: PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma. Am J Surg Pathol; 2010 Feb;34(2):137-46
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PAX2 distinguishes benign mesonephric and mullerian glandular lesions of the cervix from endocervical adenocarcinoma, including minimal deviation adenocarcinoma.
  • Mesonephric remnants of the cervix are vestiges of the embryonic mesonephric system which typically regresses during female development.
  • The differential diagnosis of exuberant mesonephric hyperplasia includes minimal deviation adenocarcinoma of the cervix, a tumor with deceptively bland morphology for which no reliable diagnostic biomarkers currently exist.
  • PAX2 encodes a transcription factor necessary in the development of the Wolffian duct system, and the protein is expressed in several tumors of mesonephric origin, including renal cell carcinoma, Wilm tumor, and nephrogenic adenoma.
  • We hypothesized that PAX2 may also be expressed in mesonephric lesions of the cervix and may distinguish mesonephric hyperplasia from minimal deviation adenocarcinoma of the cervix.
  • PAX2 was expressed in normal endocervical glands (including tunnel clusters and Nabothian cysts) (86 of 86), lobular endocervical glandular hyperplasia (5 of 5), tubal/tuboendometrioid metaplasia (8 of 8), and cervical endometriosis (13 of 14).
  • These results suggest that PAX2 immunoreactivity may be useful to (1) distinguish mesonephric hyperplasia from minimal deviation adenocarcinoma, (2) to distinguish lobular endocervical glandular hyperplasia from minimal deviation adenocarcinoma, and (3) to distinguish endocervical tubal metaplasia or cervical endometriosis from endocervical adenocarcinoma in situ.
  • Overall, a strong, diffuse nuclear PAX2 expression pattern in a cervical glandular proliferation predicts a benign diagnosis (positive predictive value 90%, negative predictive value 98%; P<0.001); however, PAX2 should not be interpreted in isolation from the architectural and cytologic features of the lesion as it may be expressed in some stage II endometrial adenocarcinomas involving the cervix.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenoma / diagnosis. Cervix Uteri / pathology. Mesonephros / pathology. Mullerian Ducts / pathology. PAX2 Transcription Factor / metabolism. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor. Cell Nucleus / metabolism. Cell Nucleus / pathology. Diagnosis, Differential. Female. Humans. Hyperplasia / diagnosis. Hyperplasia / metabolism. Immunohistochemistry / methods. Neoplasm Staging. Precancerous Conditions / diagnosis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20061933.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human
  •  go-up   go-down


8. Gombos Z, Xu X, Chu CS, Zhang PJ, Acs G: Peritumoral lymphatic vessel density and vascular endothelial growth factor C expression in early-stage squamous cell carcinoma of the uterine cervix. Clin Cancer Res; 2005 Dec 1;11(23):8364-71
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritumoral lymphatic vessel density and vascular endothelial growth factor C expression in early-stage squamous cell carcinoma of the uterine cervix.
  • PURPOSE: Lymphatic invasion and nodal metastasis plays a major role in the spread of cervical cancer; however, little is known about the mechanisms whereby tumor cells enter the lymphatic system.
  • EXPERIMENTAL DESIGN: We examined the intra- and peritumoral lymphatic vessel density (LVD) using D2-40 immunohistochemistry in 111 cervical squamous cell carcinomas and correlated them with vascular endothelial growth factor (VEGF)-C expression, clinicopathologic tumor features, and outcome.
  • RESULTS: Compared with benign cervix, intratumoral and peritumoral LVD was significantly increased (P < 0.0001).
  • High peritumoral, but not intratumoral, LVD showed significant correlation with high tumor stage, lymphatic invasion, and nodal metastasis.
  • CONCLUSIONS: Our findings suggest a potential role for VEGF-C in tumor-induced lymphangiogenesis represented by high peritumoral LVD, which may be one of the mechanisms leading to lymphatic invasion and metastatic spread.
  • High peritumoral LVD may be an independent prognostic factor in early-stage cervical cancer.
  • [MeSH-major] Lymph Nodes / pathology. Lymphatic Vessels / pathology. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology. Vascular Endothelial Growth Factor C / metabolism
  • [MeSH-minor] Carcinoma in Situ / metabolism. Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Female. Humans. Lymphangiogenesis. Lymphatic Metastasis. Neoplasm Staging. Neoplasms / metabolism. Neoplasms / pathology. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16322297.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor C
  •  go-up   go-down


9. Smith KB, Amdur RJ, Yeung AR, Morris CG, Kirwan J, Morgan LS: Postoperative radiotherapy for cervix cancer incidentally discovered after a simple hysterectomy for either benign conditions or noninvasive pathology. Am J Clin Oncol; 2010 Jun;33(3):229-32
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative radiotherapy for cervix cancer incidentally discovered after a simple hysterectomy for either benign conditions or noninvasive pathology.
  • OBJECTIVE: Report the long-term outcome of patients who received postoperative radiotherapy for incidentally discovered cervix cancer following simple hysterectomy.
  • METHODS: We recorded tumor status, treatment complications, and survival of 25 patients treated at our institution from 1961 to 2004 with postoperative RT for invasive cervix cancer discovered following simple hysterectomy (median follow-up, 17 years).
  • All patients had stage IA2-II squamous cell carcinoma (76%) or adenocarcinoma (24%) of the cervix.
  • No patient died of cervix cancer.
  • The actuarial rate of tumor control and relapse-free survival at 5, 10, and 20 years was 96%.
  • CONCLUSIONS: This series demonstrates the price we pay for adding comprehensive radiotherapy to simple hysterectomy for early-stage cervix cancer.
  • (1) Avoid postoperative radiotherapy by aggressively screening patients for invasive disease before performing simple hysterectomy. (2) Raise the threshold for delivering pelvic radiotherapy following simple hysterectomy with an incidental diagnosis of invasive cervix cancer.
  • We recommend vaginal brachytherapy alone in patients with negative postoperative imaging, negative surgical margins, and <10 mm tumor invasion.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Carcinoma, Squamous Cell / radiotherapy. Hysterectomy. Radiotherapy, Adjuvant. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Enteritis / etiology. Female. Follow-Up Studies. Hemangiosarcoma / etiology. Humans. Incidental Findings. Neoplasm Invasiveness. Neoplasm Recurrence, Local / surgery. Neoplasms, Radiation-Induced / etiology. Neoplasms, Second Primary / etiology. Postoperative Complications / etiology. Pulmonary Embolism / etiology. Radiation Injuries / etiology. Retrospective Studies. Salvage Therapy. Survival Rate. Treatment Outcome. Uterine Diseases / surgery. Vulvar Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19806037.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Comunoğlu N, Comunoğlu C, Başsüllü N, Somunkiran A, Calay Z: Müllerian adenosarcoma with sarcomatous overgrowth of the cervix: unusual large polypoid mass. Ups J Med Sci; 2007;112(1):67-72
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Müllerian adenosarcoma with sarcomatous overgrowth of the cervix: unusual large polypoid mass.
  • Müllerian adenosarcoma (MS) is a rare neoplasm of uterine cervix composed of benign epithelial and malignant stromal components.
  • In this report we present a MASO case, derived from uterine cervix of a 60 year-old-female patient presenting as a cervical polypoid mass, to our knowledge the second case of the English literature.
  • In spite of sarcomatous overgrowth, high mitotic activity and huge tumor size of 12,5 cms, it displayed no myometrial invasion, vascular invasion and heterologous elements.
  • The difficulties in diagnosis and treatment of this entity will be evaluated in this report.
  • [MeSH-major] Adenosarcoma / diagnosis. Mixed Tumor, Mullerian / diagnosis. Uterine Cervical Neoplasms / diagnosis


11. Triginelli SA, Silva-Filho AL, Traiman P, Silva FM, Chaves-Dias MC, Oliveira GC, Cunha-Melo JR: Telomerase activity in the vaginal margins of radical hysterectomy in patients with carcinoma of the cervix: correlation with histology and human papillomavirus. Int J Gynecol Cancer; 2006 May-Jun;16(3):1283-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomerase activity in the vaginal margins of radical hysterectomy in patients with carcinoma of the cervix: correlation with histology and human papillomavirus.
  • This study was undertaken to evaluate the telomerase activity both in the tumor and in the vaginal margins of radical hysterectomy in patients with squamous cell carcinoma (SCC) of the cervix.
  • Thirty-three patients with SCC of the cervix (study group) and 13 patients with uterine myoma (control group) were prospectively studied.
  • Tissue samples were taken from the tumor or cervix, anterior vaginal margin (AVM), and posterior vaginal margin (PVM).
  • The telomerase activity was significantly higher in the tumor than in the benign cervix (P < 0.001).
  • There was no difference in telomerase activity in the AVM and PVM in patients with cervical carcinoma compared to the control group.
  • Telomerase activity is a marker of histologic malignancy in patients with SCC of the cervix.
  • [MeSH-major] Carcinoma, Squamous Cell / enzymology. Hysterectomy. Neoplasm, Residual / diagnosis. Papillomaviridae / isolation & purification. Telomerase / metabolism. Uterine Cervical Neoplasms / surgery. Vagina / enzymology. Vaginal Neoplasms / enzymology. Vaginal Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. DNA Probes, HPV. Female. Humans. Middle Aged. Polymerase Chain Reaction / methods


12. Onuma K, Dabbs DJ, Bhargava R: Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium. Int J Gynecol Pathol; 2008 Jul;27(3):418-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium.
  • Mammaglobin (MGB), a secretory protein belonging to the uteroglobin/Clara cell protein family, is a sensitive marker for breast carcinoma, but is also reported to be expressed in the female genital tract and its neoplasms.
  • Endocervical adenocarcinoma in situ (AIS) showed either weak (predominantly) or moderate (occasionally) expression in about 40% of the cases in comparison with strong positivity in benign endocervical glandular epithelium.
  • Reduction of MGB staining was seen in transition from benign epithelium to AIS.
  • Most endocervical adenocarcinomas are negative for MGB, in contrast to mostly positive endometrioid endometrial adenocarcinomas, however, MGB expression alone is not specific enough to distinguish these 2 tumor types.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Carcinoma in Situ / metabolism. Neoplasm Proteins / biosynthesis. Uterine Neoplasms / metabolism. Uteroglobin / biosynthesis. Uterus / metabolism
  • [MeSH-minor] Cervix Uteri / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Female. Humans. Immunohistochemistry. Mammaglobin A. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580321.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


13. Badr RE, Walts AE, Chung F, Bose S: BD ProEx C: a sensitive and specific marker of HPV-associated squamous lesions of the cervix. Am J Surg Pathol; 2008 Jun;32(6):899-906
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BD ProEx C: a sensitive and specific marker of HPV-associated squamous lesions of the cervix.
  • BD ProEx C (ProEx C) is a recently developed immunocytochemical assay that targets the expression of topoisomerase II-alpha and minichromosome maintenance protein-2, 2 genes shown to be overexpressed in cervical cancers.
  • Recent studies validated this reagent in liquid-based cytology specimens and suggested its usefulness as an adjunct in the diagnosis of challenging cases.
  • This study aims to assess ProEx C expression patterns in benign, atypical, and dysplastic lesions of the cervix and to compare these patterns with p16 and Ki67 expression and with the presence of human papilloma virus DNA as determined by in situ hybridization.
  • ProEx C positivity was limited to the basal layers of the epithelium in 75% of benign cervices.
  • In 92% of high-grade dysplasias [cervical intraepithelial neoplasia (CIN) II and III] strong positive staining for ProEx C involved the lower and upper halves of the epithelium.
  • To summarize, ProEx C is a reliable marker for high-grade CIN that can be applied to tissue sections to confirm the diagnosis of high-grade CIN and to triage cases of atypical squamous metaplasia.
  • [MeSH-major] Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / metabolism. Cell Cycle Proteins / analysis. DNA Topoisomerases, Type II / analysis. DNA-Binding Proteins / analysis. Nuclear Proteins / analysis. Papillomavirus Infections / complications. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cervical Intraepithelial Neoplasia / diagnosis. Cervical Intraepithelial Neoplasia / metabolism. Cervical Intraepithelial Neoplasia / virology. Female. Humans. Immunohistochemistry. Middle Aged. Minichromosome Maintenance Complex Component 2. Precancerous Conditions / diagnosis. Precancerous Conditions / metabolism. Precancerous Conditions / virology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18425044.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


14. Fleming NA, Hopkins L, de Nanassy J, Senterman M, Black AY: Mullerian adenosarcoma of the cervix in a 10-year-old girl: case report and review of the literature. J Pediatr Adolesc Gynecol; 2009 Aug;22(4):e45-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mullerian adenosarcoma of the cervix in a 10-year-old girl: case report and review of the literature.
  • Müllerian adenosarcoma is a rare neoplasm usually found in postmenopausal women.
  • It is a biphasic tumor, composed of a benign epithelial component and a malignant stromal component.
  • To date, this neoplasm has been reported in only 16 adolescent girls.
  • At the level of the cervix, there were 3 polypoid gelatinous structures arising from the endocervix and extruding past the exocervix.
  • Hysteroscopic inspection of the uterine cavity did not find any abnormalities.
  • Pathology confirmed a diagnosis of müllerian adenosarcoma originating from the endocervix.
  • Uterine curettings were negative for malignancy.
  • After a thorough evaluation of the available literature, review with the Regional Tumor Board and extensive discussions with the family, a decision was made to perform a radical hysterectomy, bilateral salpingectomy, bilateral pelvic lymph node dissection, upper vaginectomy and preservation of ovaries.
  • CONCLUSION: Müllerian adenosarcoma of the endocervix is a very rare pediatric tumor.
  • Due to the rarity of this tumor in this age group, optimal therapy is uncertain.
  • [MeSH-major] Adenosarcoma / pathology. Uterine Cervical Neoplasms / pathology


15. Li C, Rock KL, Woda BA, Jiang Z, Fraire AE, Dresser K: IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression. Mod Pathol; 2007 Feb;20(2):242-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16(INK4a) expression.
  • Adenocarcinoma in situ of the uterine cervix remains a diagnostic challenge in a small proportion of cases.
  • This suggests a need for biomarker that may be of help in establishing the diagnosis.
  • Forty-four samples of adenocarcinoma in situ from 40 patients and 23 control cases of benign uterine cervix were included in this study.
  • In addition to benign endocervical epithelium, 19 of these 23 control cases also showed focal tubal metaplasia.
  • Our findings demonstrate significant expression of insulin-like growth factor-II mRNA-binding protein 3 and p16(INK4a) in adenocarcinoma in situ as compared to benign endocervical glands, suggesting that expression of these biomarkers may be helpful in the distinction of adenocarcinoma in situ from benign endocervical glands, particularly in difficult borderline cases.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Carcinoma in Situ / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Neoplasm Proteins / metabolism. RNA-Binding Proteins / metabolism. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Adult. Cervix Uteri / metabolism. Cervix Uteri / pathology. Female. Fluorescent Antibody Technique, Indirect. Humans. Immunoenzyme Techniques. Middle Aged

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17192788.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins
  •  go-up   go-down


16. Hilfrich R, Hariri J: Prognostic relevance of human papillomavirus L1 capsid protein detection within mild and moderate dysplastic lesions of the cervix uteri in combination with p16 biomarker. Anal Quant Cytol Histol; 2008 Apr;30(2):78-82
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic relevance of human papillomavirus L1 capsid protein detection within mild and moderate dysplastic lesions of the cervix uteri in combination with p16 biomarker.
  • Fifty sections were derived from a benign group, 91 from low-grade (cervical intraepithelial neoplasia [CIN 1]) lesions and 50 from high-grade (CIN 2 and 3) lesions.

  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18561743.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Capsid Proteins; 0 / HPV L1 protein, Human papillomavirus; 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Viral; 0 / P16 protein, human
  •  go-up   go-down


17. Slosar M, Vohra P, Prasad M, Fischer A, Quinlan R, Khan A: Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors. Endocr Pathol; 2009;20(3):149-57
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors.
  • It is highly expressed in carcinomas of the pancreas, stomach, colon, rectum, kidneys, uterine cervix, lung, and ovary.
  • No significant correlation was found between pathologic tumor characteristics and IMP3 expression in differentiated follicular pattern thyroid carcinoma.
  • With 100% specificity and 69% sensitivity for FC as compared to FA and 100% specificity for FVPC, again compared to FA, IMP3 has the potential to be diagnostically useful in differentiating malignant and benign follicular pattern thyroid lesions.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Biomarkers, Tumor / analysis. Neoplasm Proteins / biosynthesis. RNA-Binding Proteins / biosynthesis. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19449140.001).
  • [ISSN] 1559-0097
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA-Binding Proteins
  •  go-up   go-down


18. Korach J, Machtinger R, Perri T, Vicus D, Segal J, Fridman E, Ben-Baruch G: Villoglandular papillary adenocarcinoma of the uterine cervix: a diagnostic challenge. Acta Obstet Gynecol Scand; 2009;88(3):355-8
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Villoglandular papillary adenocarcinoma of the uterine cervix: a diagnostic challenge.
  • Villoglandular papillary adenocarcinoma (VGA) is a rare subtype of cervical adenocarcinoma.
  • The aim of our study was to evaluate the reliability of histological assessment for pre-treatment diagnosis of VGA.
  • Median age at diagnosis was 38.8 years (range 27-65).
  • Of these, only two had been correctly diagnosed preoperatively, while in three, the initial biopsies were benign or pre-malignant.
  • In four patients, the biopsy results had been interpreted as an invasive malignant tumor necessitating hysterectomy.
  • The final histological report on the remaining three patients was invasive cervical adenocarcinoma.
  • We conclude that pre-treatment diagnosis should not be based solely on a simple punch biopsy because of its low rate of diagnostic accuracy.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Cervix Uteri / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Biopsy. Diagnostic Errors. Female. Humans. Middle Aged. Neoplasm Staging


19. Dolezelova H, Slampa P, Ondrova B, Gombosova J, Sovadinova S, Novotny T, Bolcak K, Ruzickova J, Hynkova L, Forbelska M: The impact of PET with 18FDG in radiotherapy treatment planning and in the prediction in patients with cervix carcinoma: results of pilot study. Neoplasma; 2008;55(5):437-41
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of PET with 18FDG in radiotherapy treatment planning and in the prediction in patients with cervix carcinoma: results of pilot study.
  • Positron emission tomography (PET) is used to distinguish between benign and malign tumors, to diagnose relapse or post-therapeutic changes.
  • Results of this pilot study show the role of PET with 8-F-fluorodeoxyglucose ((18)FDG) for staging of cervical carcinoma and in the radiotherapeutic planning.
  • Between March 2005 and May 2007, 51 patients with cervical carcinoma were treated with combination of external beam radiotherapy and HDR brachytherapy, with or without concomitant cisplatin.
  • The results of this study confirmed the important role of PET in diagnosis and treatment of cervical carcinoma and in determination of target volumes in radiotherapy.
  • PET was found to be a standard staging examination of cervical carcinoma in Masaryk Memorial Cancer Institute.
  • [MeSH-major] Fluorodeoxyglucose F18. Positron-Emission Tomography. Uterine Cervical Neoplasms / radionuclide imaging. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Brachytherapy. Female. Humans. Middle Aged. Neoplasm Staging. Patient Care Planning. Pilot Projects. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18665755.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Slovakia
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


20. Scott ME, Ma Y, Kuzmich L, Moscicki AB: Diminished IFN-gamma and IL-10 and elevated Foxp3 mRNA expression in the cervix are associated with CIN 2 or 3. Int J Cancer; 2009 Mar 15;124(6):1379-83
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diminished IFN-gamma and IL-10 and elevated Foxp3 mRNA expression in the cervix are associated with CIN 2 or 3.
  • Cervical mucosal expression of cytokines involved in mediating cellular immunity is believed to influence the persistence of human papillomavirus (HPV) infection, a necessary prerequisite for the development of cervical intraepithelial neoplasia (CIN).
  • Using quantitative RT-PCR, we measured, in cross-sectional design, the cervical mRNA expression of IFN-gamma, IL-10, and IL-12, as well as the Treg transcription factor Forkhead box P3 (Foxp3), in a cohort of young women representing CIN 1, 2, and 3, as well as benign histology.
  • Higher levels of IFN-gamma and IL-10 were significantly (p <or= 0.05) associated with decreased odds of having high-grade cervical disease (CIN 2 or 3) in multivariate logistic regression models.
  • In a multivariate model including cervical infection with HPV16 and/or another high-risk HPV type, Foxp3 remained higher in the CIN 2/3 group, but the difference was notably less significant (p = 0.05).
  • These findings support a model in which diminished cellular immunity in the cervical mucosa and mucosal enrichment of Treg cells both contribute to the development of high-grade lesions.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 2001 Sep;195(2):179-85 [11592096.001]
  • [Cites] Eur J Immunol. 2008 Apr;38(4):928-30 [18395863.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):29-34 [12807942.001]
  • [Cites] Adv Anat Pathol. 2003 Jul;10(4):200-3 [12826825.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5449-55 [15289354.001]
  • [Cites] J Infect Dis. 1997 Apr;175(4):927-31 [9086151.001]
  • [Cites] Immunology. 1999 Feb;96(2):272-7 [10233705.001]
  • [Cites] Eur J Cancer. 1999 Mar;35(3):490-7 [10448305.001]
  • [Cites] Clin Diagn Lab Immunol. 1999 Sep;6(5):751-5 [10473530.001]
  • [Cites] Lancet. 2004 Nov 6-12;364(9446):1678-83 [15530628.001]
  • [Cites] Eur J Immunol. 2005 Jun;35(6):1681-91 [15902688.001]
  • [Cites] Biol Reprod. 2005 Dec;73(6):1253-63 [16093359.001]
  • [Cites] Semin Cancer Biol. 2006 Apr;16(2):98-105 [16378733.001]
  • [Cites] Curr Opin Immunol. 2006 Apr;18(2):214-9 [16464567.001]
  • [Cites] J Clin Immunol. 2006 May;26(3):222-32 [16783462.001]
  • [Cites] Cancer Res. 2007 Jan 1;67(1):354-61 [17210718.001]
  • [Cites] Trends Mol Med. 2007 Mar;13(3):108-16 [17257897.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):12087-92 [17615234.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1749-55 [17582606.001]
  • [Cites] Clin Exp Immunol. 2007 Nov;150(2):199-209 [17937675.001]
  • [Cites] Eur J Immunol. 2008 Apr;38(4):925-7 [18395862.001]
  • [Cites] J Clin Immunol. 2002 Jan;22(1):23-7 [11958590.001]
  • (PMID = 19089920.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA087905; United States / NCI NIH HHS / CA / CA051323-15; United States / NCI NIH HHS / CA / R01 CA087905-05S1; United States / NCI NIH HHS / CA / 2 R01 CA87905; United States / NCI NIH HHS / CA / R01 CA051323-15; United States / NCI NIH HHS / CA / R01 CA051323; United States / NCI NIH HHS / CA / R37 CA051323-19; United States / NCI NIH HHS / CA / CA051323-19; United States / NCI NIH HHS / CA / CA087905-05S1; United States / NCI NIH HHS / CA / 2 R37 CA051323; United States / NCI NIH HHS / CA / 2 R01 CA51323; United States / NCI NIH HHS / CA / R37 CA051323
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 130068-27-8 / Interleukin-10; 63231-63-0 / RNA; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ NIHMS98768; NLM/ PMC2696072
  •  go-up   go-down


21. Rezvani M, Shaaban A: Imaging of cervical pathology. Clin Obstet Gynecol; 2009 Mar;52(1):94-111
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of cervical pathology.
  • A variety of benign and malignant entities affect the uterine cervix.
  • Cross-sectional and functional imaging can improve the accuracy of traditional clinical cervical cancer staging.
  • The imaging appearance of benign cervical pathology is reviewed with ultrasonography as the first-line imaging modality and magnetic resonance imaging for problem solving in difficult cases.
  • [MeSH-major] Cervix Uteri / pathology. Magnetic Resonance Imaging / methods. Ultrasonography / methods. Uterine Cervical Diseases / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Neoplasm Staging. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods


22. Sahdev A: Cervical tumors. Semin Ultrasound CT MR; 2010 Oct;31(5):399-413
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cervical tumors.
  • Imaging the cervix for benign and malignant disease can be achieved using transvaginal ultrasound, computed tomography (CT), magnetic resonance imaging, and 18-fluorodeoxyglucose positron emission tomography.
  • The best established role of imaging is in cervical carcinoma where magnetic resonance imaging, CT and increasingly positron emission tomography-CT are the most frequently used imaging modalities.
  • Histopathological diagnosis of cervical disorders cannot be made on the basis of imaging alone but certain imaging features may provide an indication as to the underlying diagnosis.
  • We describe the imaging features of some malignant tumor subtypes in which a preoperative diagnosis may alter management.
  • Benign lesions of the cervix are usually detected incidentally or during investigations for dysfunctional vaginal bleeding.
  • We describe the imaging features of the commonly encountered benign cervical lesions.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Neoplasm Recurrence, Local / diagnosis. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Cervix Uteri / pathology. Cervix Uteri / radiography. Cervix Uteri / radionuclide imaging. Diagnosis, Differential. Female. Fluorodeoxyglucose F18. Humans. Lymphatic Metastasis. Neoplasm Staging. Radiopharmaceuticals. Radiotherapy Planning, Computer-Assisted / methods. Uterine Cervical Diseases / diagnosis


23. Mikami Y, Kiyokawa T, Moriya T, Sasano H: Immunophenotypic alteration of the stromal component in minimal deviation adenocarcinoma ('adenoma malignum') and endocervical glandular hyperplasia: a study using oestrogen receptor and alpha-smooth muscle actin double immunostaining. Histopathology; 2005 Feb;46(2):130-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: To define the phenotypic alteration of the stromal component in association with destructive invasion which is a crucial feature in distinguishing minimal deviation adenocarcinoma (MDA) from benign endocervical glandular lesions.
  • METHODS AND RESULTS: We studied endocervical glandular hyperplasias including non-specific-type (NEGH) (n = 3) and lobular-type (LEGH) (n = 8), and minimal deviation adenocarcinoma (MDA) (n = 11), well-differentiated endocervical adenocarcinoma of usual-type (WDA) (n = 11), and adenocarcinoma in situ (AIS) (n = 6) of the cervix, by double immunostaining for oestrogen receptor (ER) and alpha-smooth muscle actin (alpha-SMA) using peroxidase- and alkaline phosphatase-polymer methods, respectively.
  • [MeSH-major] Actins / analysis. Adenocarcinoma / pathology. Cervix Uteri / pathology. Receptors, Estrogen / analysis. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Hyperplasia. Immunohistochemistry / methods. Metaplasia. Muscle, Smooth / chemistry. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15693884.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Actins; 0 / Receptors, Estrogen
  •  go-up   go-down


24. Chivukula M, Domfeh A, Carter G, Tseng G, Dabbs DJ: Characterization of high-grade ductal carcinoma in situ with and without regressive changes: diagnostic and biologic implications. Appl Immunohistochem Mol Morphol; 2009 Dec;17(6):495-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Regressive changes (RC) have been described in malignant melanoma, carcinomas of the prostate and cervix.
  • The presence of RC in these neoplasms may signify some degree of host response to tumor and seems to be a sign of poor prognosis for some neoplasms.
  • It is also critically important to recognize HGDCIS-RC for diagnostic purposes, as the differential diagnosis of RC includes, benign associations such as papilloma, fibrocystic changes and periductal mastitis.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19407654.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 13
  •  go-up   go-down


25. Brown L: Pathology of uterine malignancies. Clin Oncol (R Coll Radiol); 2008 Aug;20(6):433-47
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathology of uterine malignancies.
  • This overview covers epithelial, stromal and mesenchymal malignancies of the body of the uterus, excluding the cervix.
  • The distinction of type I and type II endometrial adenocarcinoma with the morphological variants of this tumour is discussed and some molecular aspects are explored.
  • Some types of mixed epithelial and stromal neoplasm are described and contrasted with carcinosarcoma.
  • The concept of stromal sarcoma and high-grade uterine sarcoma is described and an outline of malignant smooth muscle tumours of the uterus includes a description of smooth muscle tumours of uncertain malignant potential and worrying benign smooth muscle lesions.
  • [MeSH-major] Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Endometrial Stromal Tumors / pathology. Female. Humans. Leiomyosarcoma / pathology. Mesoderm / pathology. Neoplasms, Glandular and Epithelial / pathology. Sarcoma / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18499412.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 233
  •  go-up   go-down


26. López-Morales D, Velázquez-Márquez N, Valenzuela O, Santos-López G, Reyes-Leyva J, Vallejo-Ruiz V: Enhanced sialyltransferases transcription in cervical intraepithelial neoplasia. Invest Clin; 2009 Mar;50(1):45-53
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhanced sialyltransferases transcription in cervical intraepithelial neoplasia.
  • Altered sialylation observed during oncogenic transformation, tumor metastases and invasion, has been associated with enhanced sialyltransferases (STs) transcription.
  • Increased mRNA expression of STs (ST6Gal I, ST3Gal III) has been detected in invasive cervical squamous cell carcinoma.
  • A study of the sialic acid concentration in local tissue of cervix and in serum showed a slight elevation in benign inflammatory lesions and a moderate elevation in severe neoplasia, but to date, altered expression of STs in cervical intraepithelial neoplasia has not yet been evaluated.
  • This study investigates the changes in mRNA expression of three STs (ST6Gal I, ST3Gal III, and ST3Gal IV) in cervical intraepithelial lesions (CIN).
  • Alterations of these STs mRNA expression were examined in 35 cervix specimens classified as normal, CIN 1, CIN 2 and CIN 3, by semiquantitative reverse transcription-polymerase chain reaction, mRNA expression of the three STs was enhanced in CIN 1, CIN 2 and CIN 3 with respect to normal tissue, with a significant difference of p < 0.001 (Mann-Whitney U test) for all the enzymes.
  • [MeSH-major] Cervical Intraepithelial Neoplasia / enzymology. Neoplasm Proteins / genetics. RNA, Messenger / biosynthesis. RNA, Neoplasm / biosynthesis. Sialyltransferases / genetics. Uterine Cervical Neoplasms / enzymology

  • Genetic Alliance. consumer health - Cervical Intraepithelial Neoplasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19418726.001).
  • [ISSN] 0535-5133
  • [Journal-full-title] Investigación clínica
  • [ISO-abbreviation] Invest Clin
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Venezuela
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 2.4.99.- / Sialyltransferases; GZP2782OP0 / N-Acetylneuraminic Acid
  •  go-up   go-down


27. Ben Hmid R, Mourali M, Zghal D, Mahjoub S, Naceur C, Sbai N, Zouari F: [Usefulness of colposcopy in inflammatory cervico-vaginal smears: apropos of 140 cases]. Tunis Med; 2007 Jun;85(6):500-4
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Apport de la colposcopie dans les frottis cervico-vaginaux inflammatoires: a propos de 140 cas.
  • BACKGROUND: The cervical cancer is the second most frequent cancer of the woman in Tunisia.
  • AIM: The purpose of our study is to proove that an inflammatory cervical smear should be considered as a positive test and must lead to other investigations.
  • METHODS: It is a prospective study over 140 cases of inflammatory cervical smears (without atypical cells) diagnosed during a year period from june 2001 to june 2002.
  • It showed benign lesions such as: ectropion in 22.85%, colpitis in 14.28%, cervical polypus in 5%, normal transformation zone in 8.57%, but also suspicious lesions such as : atypical transformations grade I (ATGI) in 25.71% and atypical transformations grade II (ATGII) in 13.57%.
  • It makes a minutious study of the cervix and diminishes the rate of false negative made by the cervical smear.
  • [MeSH-major] Colposcopy. Uterine Cervical Neoplasms / diagnosis. Vaginal Smears
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Biopsy. Carcinoma in Situ / pathology. Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / pathology. Female. Humans. Middle Aged. Neoplasm Invasiveness. Polyps / pathology. Prospective Studies. Sexual Behavior. Uterine Cervical Diseases / pathology. Uterine Cervical Dysplasia / pathology. Uterine Cervicitis / pathology. Vaginitis / pathology


28. Stübinger SH, van der Horst Ch, Braun PM: [Pelvic tumors in the eyes of urologists]. Ther Umsch; 2007 Jul;64(7):395-8
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign tumors such as endometrial myoma, ovarian cyst and adenoma of the colon might lead to the development of urogenital symptoms.
  • This is also the case with malignant tumors of the uterus, ovaries, cervix and colon where infiltration of the urogenital organs might be noted.
  • These are the symptoms that lead to the diagnosis of the primary tumor.
  • It has to be kept in mind that urogenital tumors with such symptoms have to be included in the differential diagnosis.
  • The possibility of eradicating the tumor is then to be discussed after relieving the obstruction.
  • [MeSH-major] Pelvic Neoplasms. Prostatic Hyperplasia. Prostatic Neoplasms. Urethral Neoplasms. Urinary Bladder Neoplasms
  • [MeSH-minor] Cystectomy. Cystoscopy. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Neoplasm Staging. Prostatectomy. Quality of Life. Urinary Bladder / pathology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Enlarged Prostate (BPH).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17948757.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


29. Liao SY, Rodgers WH, Kauderer J, Bonfiglio TA, Walker JL, Darcy KM, Carter R, Hatae M, Levine L, Spirtos NM, Stanbridge EJ: Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States. Int J Cancer; 2009 Nov 15;125(10):2434-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States.
  • High-risk human papillomavirus (H-HPV) infection is strongly linked to cervical neoplasia, but its role in detecting glandular lesions (GLs) is unclear.
  • In the cervix, carbonic anhydrase IX (CA-IX) is expressed in cervical neoplasia, but rarely in the benign cervix.
  • The diagnostic utility of these biomarkers was evaluated in women with a cytologic diagnosis of atypical glandular cells (AGC).
  • Of 403 patients, 111 (28%) were positive for significant cervical lesions (SCLs) including CIN2, CIN3, adenocarcinoma in situ or invasive carcinoma.
  • The combination of CA-IX with H-HPV testing does not improve the diagnostic accuracy for cervical neoplasia in women with AGC diagnosis over that of H-HPV testing alone.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1999 Jul;30(7):816-25 [10414501.001]
  • [Cites] Am J Obstet Gynecol. 1998 Aug;179(2):382-90 [9731842.001]
  • [Cites] Diagn Cytopathol. 2006 Mar;34(3):235-9 [16470857.001]
  • [Cites] Am J Obstet Gynecol. 2005 Aug;193(2):559-65; discussion 565-7 [16098895.001]
  • [Cites] Vaccine. 2008 Aug 19;26 Suppl 10:K1-16 [18847553.001]
  • [Cites] Int J Gynecol Cancer. 2006 May-Jun;16(3):1007-13 [16803477.001]
  • [Cites] J Clin Microbiol. 2006 Nov;44(11):3915-7 [16971652.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer. 2000 Mar 1;88(5):1108-21 [10699902.001]
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):97-105 [10926787.001]
  • [Cites] Am J Pathol. 2000 Oct;157(4):1055-62 [11021808.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):905-19 [11238039.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3660-8 [11504747.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6394-9 [11522632.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):222-7 [11668502.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):96-102 [11789738.001]
  • [Cites] Cancer. 2002 Feb 25;96(1):1-4 [11836696.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2114-9 [11966386.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2120-9 [11966387.001]
  • [Cites] Diagn Cytopathol. 2003 Nov;29(5):271-9 [14595795.001]
  • [Cites] Am J Clin Pathol. 2004 Jan;121(1):87-92 [14750245.001]
  • [Cites] Gynecol Oncol. 1989 Oct;35(1):1-7 [2792895.001]
  • [Cites] Acta Cytol. 1993 Mar-Apr;37(2):115-24 [8465628.001]
  • [Cites] Int J Cancer. 1993 May 8;54(2):268-74 [8486430.001]
  • [Cites] Am J Pathol. 1994 Sep;145(3):598-609 [8080042.001]
  • [Cites] Oncogene. 1994 Oct;9(10):2877-88 [8084592.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jul;5(7):549-57 [8827360.001]
  • [Cites] Gynecol Oncol. 1996 Oct;63(1):14-8 [8898161.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):2827-31 [9230182.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1248-54 [18483347.001]
  • (PMID = 19670419.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA037517-25; United States / NCI NIH HHS / CA / CA027469-29; United States / NCI NIH HHS / CA / CA 11479; United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / U10 CA027469; United States / NCI NIH HHS / CA / U10 CA037517; None / None / / U10 CA037517-25; United States / NCI NIH HHS / CA / CA 37517; United States / NCI NIH HHS / CA / U10 CA027469-29
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA, Viral; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  • [Other-IDs] NLM/ NIHMS137629; NLM/ PMC2779726
  •  go-up   go-down


30. Janssen J: [(E)US elastography: current status and perspectives]. Z Gastroenterol; 2008 Jun;46(6):572-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The relative stiffness of the tissues within this area is described by colours superimposing on the B-mode image.
  • Several studies have demonstrated that real-time elastography is feasible and improves the diagnostic accuracy for tumours of the breast, the prostate, the cervix, and the thyroid gland.
  • For the differentation between benign and malignant lymph nodes, the accuracy is reported to be 85 % to 90 %.
  • Therefore, the early diagnosis of cancer within chronic pancreatitis will probably not be improved by elastography.
  • [MeSH-major] Elasticity Imaging Techniques / methods. Endosonography / methods. Image Processing, Computer-Assisted / methods. Lymphatic Metastasis / ultrasonography. Neoplasms / ultrasonography
  • [MeSH-minor] Diagnosis, Differential. Humans. Neoplasm Staging. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / ultrastructure. Pancreatitis / pathology. Pancreatitis / ultrasonography. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18537085.001).
  • [ISSN] 0044-2771
  • [Journal-full-title] Zeitschrift für Gastroenterologie
  • [ISO-abbreviation] Z Gastroenterol
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 36
  •  go-up   go-down


31. Wang X, Kumar D, Seidman JD: Uterine lipoleiomyomas: a clinicopathologic study of 50 cases. Int J Gynecol Pathol; 2006 Jul;25(3):239-42
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uterine lipoleiomyomas: a clinicopathologic study of 50 cases.
  • Lipoleiomyoma is an uncommon uterine neoplasm and, although presumed to be benign, has been inadequately studied.
  • Confirming the benign nature of this tumor is important because it can closely resemble well-differentiated liposarcoma.
  • We evaluated 50 consecutive lipoleiomyomas diagnosed at the Washington Hospital Center from 1998 to 2004; 2.1% of patients who had uterine leiomyomas during this period had a lipoleiomyoma.
  • The mean and median tumor size was 4.6 and 2.1 cm, respectively.
  • Forty-three (83%) tumors were located in the uterine corpus, and 7 (13%) were in the cervix.
  • One broad ligament tumor and one retroperitoneal tumor were also studied.
  • There were no recurrences or fatalities related to tumor.
  • Lipoleiomyoma of the uterus seems to have an uneventful clinical course and can now be confidently regarded as benign.
  • [MeSH-major] Leiomyoma / pathology. Lipoma / pathology. Uterine Cervical Neoplasms / pathology. Uterine Neoplasms / pathology


32. Gallardo A, Prat J: Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma. Am J Surg Pathol; 2009 Feb;33(2):278-88
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mullerian adenosarcomas are rare mixed tumors of low malignant potential that occur mainly in the uterus and also in extrauterine locations.
  • Thirty-seven tumors were of the uterine corpus, 11 of the cervix, 4 of the ovary, and 1 each of the fallopian tube, vagina, and Douglas peritoneum.
  • Of 30 tumors of the uterine corpus, 17 were stage IA, 11 stage IB, 1 stage IC, and 1 stage IIIC.
  • Four cervical tumors were stage IB.
  • The tumor of the fallopian tube was stage IC, and the tumors of the vagina and recto-uterine pouch were confined to their site of origin.
  • Most uterine tumors were polypoid masses ranging from 1 to 20 cm (mean: 6.5 cm).
  • Fourteen of 30 uterine tumors (47%) had myometrial invasion that was minimal in 5, involved one-third of the myometrial thickness in 7, and more than 50% in 2.
  • Of 4 cervical tumors, 2 were endocervical polyps, 1 invaded one-third of the cervical wall, and the other invaded its full thickness.
  • Six developed metastases and 5 of them died of tumor.
  • Four had adenosarcomas with sarcomatous overgrowth; however, the other 2 patients had typical low-grade adenosarcomas of the uterine corpus and cervix, respectively, exhibiting only mild nuclear atypia of the stromal component and </=2 mitotic figures/10 high power fields.
  • The finding of such cases, which raises the controversy of whether or not adenofibroma exists as a tumor entity, prompted us to make a comparative immunohistochemical analysis of 23 typical adenosarcomas, 8 adenosarcomas with sarcomatous overgrowth, and 29 benign and malignant related lesions, including 7 clinically benign adenofibromas.
  • Adenosarcomas with sarcomatous overgrowth showed strong immunoreaction for Ki-67 and p53 and loss of CD10 and progesterone receptors immunostaining; in contrast, the immunoreaction for these tumor markers in typical adenosarcomas without sarcomatous overgrowth was similar to that of adenofibromas associated with favorable outcome and other benign lesions such as endometrial polyps and endometriosis.
  • [MeSH-major] Adenofibroma / pathology. Adenosarcoma / pathology. Genital Neoplasms, Female / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Mitotic Index. Neoplasm Staging. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18941402.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


33. Horn LC, Dallacker M, Bilek K: [Carcinosarcomas (malignant mixed Mullerian tumors) of the uterus. Morphology, pathogenetic aspects and prognostic factors]. Pathologe; 2009 Jul;30(4):292-301
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Carcinosarcomas (malignant mixed Mullerian tumors) of the uterus. Morphology, pathogenetic aspects and prognostic factors].
  • [Transliterated title] Karzinosarkome (maligne Müller-Mischtumoren) des Uterus. Morphologie, molekulare Pathogenese und morphologische Prognosefaktoren.
  • The strongest prognostic factor is tumor stage followed by lymph node metastases, deep myometrial infiltration, involvement of the cervix and tumor size.
  • The main differential diagnoses include uterine sarcomas, adenosarcoma and benign metaplastic change within the endometrium.
  • [MeSH-major] Carcinosarcoma / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Carcinoma, Endometrioid / pathology. Cervix Uteri / pathology. Female. Humans. Immunohistochemistry / methods. Lymphatic Metastasis. Myometrium / pathology. Neoplasm Staging. Prognosis. Survival Rate. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2005 Dec;6(12):961-71 [16321764.001]
  • [Cites] Gynecol Oncol. 1997 Dec;67(3):316-21 [9441781.001]
  • [Cites] Int J Gynecol Pathol. 1990;9(1):1-19 [2152890.001]
  • [Cites] Gynecol Oncol. 2005 Aug;98(2):274-80 [15972232.001]
  • [Cites] Cancer. 2000 Jun 15;88(12):2782-6 [10870061.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):684-7 [16797683.001]
  • [Cites] Anticancer Res. 2001 Jul-Aug;21(4B):3069-74 [11712812.001]
  • [Cites] J Clin Pathol. 2002 May;55(5):321-5 [11986333.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):786-96 [14967435.001]
  • [Cites] Int J Gynecol Pathol. 2003 Jan;22(1):75-82 [12496702.001]
  • (PMID = 19495763.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


34. Kalyanasundaram K, Ganesan R, Perunovic B, McCluggage WG: Diffusely infiltrating endometrial carcinomas with no stromal response: report of a series, including cases with cervical and ovarian involvement and emphasis on the potential for misdiagnosis. Int J Surg Pathol; 2010 Apr;18(2):138-43
International Agency for Research on Cancer - Screening Group. diagnostics - Planning and Implementing Cervical Cancer Prevention and Control Programs: A Manual for Managers .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusely infiltrating endometrial carcinomas with no stromal response: report of a series, including cases with cervical and ovarian involvement and emphasis on the potential for misdiagnosis.
  • Endometrial carcinomas, particularly of endometrioid type, can invade the myometrium or cervix without eliciting a stromal desmoplastic or inflammatory response and have been referred to as diffusely infiltrating endometrial carcinomas.
  • The neoplasms consisted of 12 endometrioid carcinomas, 1 mixed endometrioid and clear cell carcinoma, and 1 serous carcinoma.
  • Seven cases exhibited cervical stromal involvement and in 2 there was involvement of both ovaries in a similar pattern.
  • Several of the cases were seen in consultation and the pattern of infiltration raised a number of differential diagnoses, both benign and malignant, depending on the site of tumor involvement, including adenomyosis, adenomyoma, primary endocervical glandular lesions, cervical mesonephric remnants, endometriosis or tuboendometrioid metaplasia, and ovarian cortical inclusion cysts.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnostic Errors / prevention & control. Female. Humans. Middle Aged. Myometrium / pathology. Neoplasm Invasiveness. Stromal Cells / pathology


35. Plesinac-Karapandzic V, Perisic Z, Milovanovic Z, Vukicevic D, Mileusnic D, Stevanovic J, Rakocevic Z, Saric M: Invasive inflammatory pseudotumor of the pelvis: a case report with review of the literature. J BUON; 2009 Apr-Jun;14(2):301-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inflammatory pseudotumor (IPT) is a rare benign lesion of unknown etiology, which mimics malignant neoplasm and may arise from various organs.
  • On bimanual vaginal and rectal examination, a mass was involving the uterus, parametria and mostly left adnexa, while the cervix appeared normal.
  • Computed tomographic (CT) scan revealed a 13x10.5 cm mass in the pelvis, mostly at the place of the left adnexa, uterus and both parametria, also involving the surrounding tissues and producing bilateral hydroureteronephrosis.
  • The last follow-up CT, 20 months after laparotomy, revealed no evidence of tumor.
  • [MeSH-major] Granuloma, Plasma Cell / pathology. Pelvic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19650182.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


36. Sanati S, Huettner P, Ylagan LR: Role of ProExC: a novel immunoperoxidase marker in the evaluation of dysplastic squamous and glandular lesions in cervical specimens. Int J Gynecol Pathol; 2010 Jan;29(1):79-87
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of ProExC: a novel immunoperoxidase marker in the evaluation of dysplastic squamous and glandular lesions in cervical specimens.
  • Our purpose was to evaluate the sensitivity, specificity, and predictive value of ProExC in dysplastic squamous and glandular lesions of the cervix.
  • ProExC had sensitivity, specificity, and positive and negative predictive value of 89%, 100%, 100%, and 82%, respectively, for distinguishing high-grade squamous intraepithelial lesion from squamous metaplasia, and 93%, 100%, 100%, and 98%, respectively, for distinguishing adenocarcinoma in situ from reactive benign endocervix.
  • ProExC is a valuable marker for distinguishing dysplastic squamous and endocervical lesions of the cervix from squamous metaplasia in histologic sections.
  • ProExC may eventually be used in conjunction with morphologic and human papillomavirus evaluation for better classification of indeterminate cervical lesions in Papanicolaou smears.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cervical Intraepithelial Neoplasia / diagnosis. Immunoenzyme Techniques. Uterine Cervical Dysplasia / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Antigens, Neoplasm / biosynthesis. Cell Cycle Proteins / biosynthesis. DNA Topoisomerases, Type II / biosynthesis. DNA-Binding Proteins / biosynthesis. Female. Humans. Middle Aged. Minichromosome Maintenance Complex Component 2. Nuclear Proteins / biosynthesis. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19952938.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


37. Hammes LS, Tekmal RR, Naud P, Edelweiss MI, Kirma N, Valente PT, Syrjänen KJ, Cunha-Filho JS: Up-regulation of VEGF, c-fms and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease. Gynecol Oncol; 2008 Sep;110(3):445-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Up-regulation of VEGF, c-fms and COX-2 expression correlates with severity of cervical cancer precursor (CIN) lesions and invasive disease.
  • OBJECTIVES: To describe the expression of vascular endothelial growth factor (VEGF), proto-oncogene macrophage colony-stimulating factor receptor (c-fms) and cyclooxygenase-2 (COX-2) in cervical carcinogenesis and to analyze the correlation of VEGF with c-fms and COX-2 expression.
  • METHODS: In this study, 26 cases of benign cervix, 28 low-grade cervical intraepithelial neoplasia (CIN; CIN 1), 30 high-grade CIN (CIN 2/3) and 28 squamous cervical carcinomas (SCC) were examined by immunohistochemistry (IHC) and analysis was performed separately for epithelium and stroma.
  • RESULTS: Positive epithelial expressions in normal cervix, low-grade CIN, high-grade CIN and SCC were, respectively: VEGF - 11.5%, 39.3%, 53.3% and 75% (P<0.001); c-fms - 0%, 10.7%, 40% and 67.9% (P<0.001); COX-2 - 7.7%, 39.3%, 80% and 100% (P<0.001).
  • CONCLUSIONS: On the basis of our findings, these factors may participate in the development and progression of CIN lesions, with possible interaction of c-fms and COX-2 on VEGF expression, and may be potential molecular targets for studies of cervical cancer prevention and treatment.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Cervical Intraepithelial Neoplasia / metabolism. Cyclooxygenase 2 / biosynthesis. Receptor, Macrophage Colony-Stimulating Factor / biosynthesis. Uterine Cervical Neoplasms / metabolism. Vascular Endothelial Growth Factor A / biosynthesis
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Neoplasm Invasiveness. Neoplasm Staging. Neovascularization, Pathologic / genetics. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / pathology. Up-Regulation

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18565574.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA54174
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 1.14.99.1 / Cyclooxygenase 2; EC 2.7.10.1 / Receptor, Macrophage Colony-Stimulating Factor
  •  go-up   go-down


38. Conesa-Zamora P, Doménech-Peris A, Orantes-Casado FJ, Ortiz-Reina S, Sahuquillo-Frías L, Acosta-Ortega J, García-Solano J, Pérez-Guillermo M: Effect of human papillomavirus on cell cycle-related proteins p16, Ki-67, Cyclin D1, p53, and ProEx C in precursor lesions of cervical carcinoma: a tissue microarray study. Am J Clin Pathol; 2009 Sep;132(3):378-90
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of human papillomavirus on cell cycle-related proteins p16, Ki-67, Cyclin D1, p53, and ProEx C in precursor lesions of cervical carcinoma: a tissue microarray study.
  • In-depth study of cell cycle proteins and human papillomavirus (HPV) genotyping can provide useful information about the malignant potential of precursor lesions of cervical carcinoma (CC).
  • Immunostaining of cell cycle-related proteins (p16, cyclin D1, Ki-67, p53, and ProEx C) was evaluated using tissue microarrays, and HPV genotypes were identified in 144 cervical tissue specimens encompassing normal or benign epithelial lesions, low- and high-grade squamous intraepithelial lesions (LSIL and HSIL, respectively), and CC.
  • Immunohistochemical assessment of cell cycle proteins may help to distinguish normal and benign conditions of the cervix from precursor lesions of CC.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cell Cycle / physiology. Papillomavirus Infections / metabolism. Precancerous Conditions / virology. Uterine Cervical Neoplasms / virology
  • [MeSH-minor] Antigens, Neoplasm / biosynthesis. Cell Cycle Proteins / biosynthesis. Cyclin D1 / biosynthesis. DNA Topoisomerases, Type II / biosynthesis. DNA-Binding Proteins / biosynthesis. Female. Humans. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Minichromosome Maintenance Complex Component 2. Neoplasm Proteins / biosynthesis. Nuclear Proteins / biosynthesis. Tissue Array Analysis. Tumor Suppressor Protein p53 / biosynthesis

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19687314.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / P16 protein, human; 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1; EC 3.6.4.12 / MCM2 protein, human; EC 3.6.4.12 / Minichromosome Maintenance Complex Component 2; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


39. Tang L, Dai DL, Su M, Martinka M, Li G, Zhou Y: Aberrant expression of collagen triple helix repeat containing 1 in human solid cancers. Clin Cancer Res; 2006 Jun 15;12(12):3716-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In benign nevi and noninvasive melanoma biopsies, there was little CTHRC1 protein expression.
  • Finally, transcription survey in 19 types of human solid cancers revealed aberrant CTHRC1 expression in 16 cancer types, especially cancers of the gastrointestinal tract, lung, breast, thyroid, ovarian, cervix, liver, and the pancreas.
  • [MeSH-major] Extracellular Matrix Proteins / genetics. Gene Expression Regulation, Neoplastic. Neoplasms / genetics
  • [MeSH-minor] Amino Acid Sequence. Animals. Base Sequence. DNA Primers. Humans. Immunohistochemistry. Neoplasm Invasiveness. Neoplasm Metastasis. Polymerase Chain Reaction. RNA Interference. Rabbits. Repetitive Sequences, Amino Acid

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16778098.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CTHRC1 protein, human; 0 / DNA Primers; 0 / Extracellular Matrix Proteins
  •  go-up   go-down


40. Hayashi T, Horiuchi A, Sano K, Hiraoka N, Kanai Y, Shiozawa T, Tonegawa S, Konishi I: Mice-lacking LMP2, immuno-proteasome subunit, as an animal model of spontaneous uterine leiomyosarcoma. Protein Cell; 2010 Aug;1(8):711-7
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mice-lacking LMP2, immuno-proteasome subunit, as an animal model of spontaneous uterine leiomyosarcoma.
  • Uterine tumors are the most common type of gynecologic neoplasm.
  • Uterine leiomyosarcoma (LMS) is rare, accounting for 2% to 5% of tumors of the uterine body.
  • Uterine LMS develops more often in the muscle tissue layer of the uterine body than in the uterine cervix.
  • The development of gynecologic tumors is often correlated with female hormone secretion; however, the development of uterine LMS is not substantially correlated with hormonal conditions, and the risk factors are not yet known.
  • Radiographic evaluation combined with PET/CT can be useless in the diagnosis and surveillance of uterine LMS.
  • Importantly, a diagnostic biomarker, which distinguishes malignant LMS and benign tumor leiomyoma (LMA) is yet to be established.
  • Accordingly, it is necessary to analyze risk factors associated with uterine LMS in order to establish a method of treatment.
  • LMP2-deficient mice spontaneously develop uterine LMS, with a disease prevalence of ∼40% by 14 months of age.
  • It is therefore of interest whether human uterine LMS shows a loss of LMP2 expression.
  • LMP2 is potentially a diagnostic biomarker for uterine LMS, and gene therapy with LMP2-encording DNA may be a new therapeutic approach.
  • [MeSH-major] Cysteine Endopeptidases / genetics. Leiomyosarcoma / genetics. Proteasome Endopeptidase Complex / metabolism. Uterine Neoplasms / genetics
  • [MeSH-minor] Animals. Biomarkers, Tumor / biosynthesis. Biomarkers, Tumor / genetics. Down-Regulation. Female. Gene Deletion. Humans. Interferon Regulatory Factor-1 / biosynthesis. Interferon Regulatory Factor-1 / genetics. Leiomyoma / metabolism. Mice. Mice, Knockout

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21203912.001).
  • [ISSN] 1674-8018
  • [Journal-full-title] Protein & cell
  • [ISO-abbreviation] Protein Cell
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interferon Regulatory Factor-1; 144416-78-4 / LMP-2 protein; EC 3.4.22.- / Cysteine Endopeptidases; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  • [Other-IDs] NLM/ PMC4875197
  •  go-up   go-down


41. Bhosale P, Peungjesada S, Devine C, Balachandran A, Iyer R: Role of magnetic resonance imaging as an adjunct to clinical staging in cervical carcinoma. J Comput Assist Tomogr; 2010 Nov-Dec;34(6):855-64
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of magnetic resonance imaging as an adjunct to clinical staging in cervical carcinoma.
  • Magnetic resonance imaging depicts the morphological details of the female pelvis and is useful for evaluating both benign and malignant cervical masses.
  • Clinical assessment of the extent of cervical cancer is crucial in determining the optimal treatment strategy, but clinical staging by itself has limitations.
  • The prognosis of cervical cancer is determined not only by stage, but also by nodal status, tumor volume, and depth of invasion, none of which are included in the FIGO guidelines.
  • Magnetic resonance imaging has been described as the most accurate, noninvasive imaging modality in staging cervical carcinoma.
  • This review outlines the magnetic resonance features of normal cervix, primary disease (by stage), and recurrent disease and discusses the role of magnetic resonance imaging in staging and clinical decision making.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Contrast Media. Female. Humans. Lymphatic Metastasis / pathology. Neoplasm Staging. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21084900.001).
  • [ISSN] 1532-3145
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


42. Agur W, Hassan M, Laban M, Morsi H, Abou-Senna I: The relationship between bcl-2 oncogene expression and clinicopathological criteria in various stages of cervical neoplasia in Egyptian women. Eur J Gynaecol Oncol; 2010;31(5):536-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship between bcl-2 oncogene expression and clinicopathological criteria in various stages of cervical neoplasia in Egyptian women.
  • PURPOSE: To assess the degree of bcl-2 expression in the various stages of cervical neoplasia in a sample population of Egyptian women and relate the findings to clinicopathological criteria of invasive cervical cancer.
  • METHODS: Bcl-2 protein expression was assessed by immuno-histochemistry in 40 patients with cervical neoplasia (intraepithelial and invasive) in comparison to 20 patients with benign changes.
  • Patients with invasive disease were followed up 2 years later and the outcome was correlated to the bcl-2 status at the time of diagnosis.
  • RESULTS: Bcl-2 expression increased from 20% in normal cervical tissue to 42.9% in cervical intraepithelial neoplasia grade II then dropped to 33% in invasive disease.
  • CONCLUSION: Bcl-2 expression is reduced along the spectrum from benign towards invasive disease of the cervix.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cervical Intraepithelial Neoplasia / metabolism. Cervical Intraepithelial Neoplasia / pathology. Proto-Oncogene Proteins c-bcl-2 / metabolism. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Case-Control Studies. Cross-Sectional Studies. Egypt. Female. Humans. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21061795.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


43. Gong L, Zhang WD, Liu XY, Han XJ, Yao L, Zhu SJ, Lan M, Li YH, Zhang W: Clonal status and clinicopathological observation of cervical minimal deviation adenocarcinoma. Diagn Pathol; 2010;5:25
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonal status and clinicopathological observation of cervical minimal deviation adenocarcinoma.
  • BACKGROUND: Minimal deviation adenocarcinoma (MDA) of the uterine cervix is defined as an extremely well differentiated variant of cervical adenocarcinoma, with well-formed glands that resemble benign glands but show distinct nuclear anaplasia or evidence of stromal invasion.
  • Thus, MDA is difficult to differentiate from other cervical hyperplastic lesions.
  • Thus, our findings indicate that MDA is a true neoplasm but is not associated with high-risk HPV.
  • CONCLUSIONS: Diagnosis of MDA depends mainly on its clinical manifestations, the pathological feature that MDA glands are located deeper than the lower level of normal endocervical glands, and immunostaining.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Cell Differentiation. Chromosomes, Human, X. Receptors, Androgen / genetics. Uterine Cervical Neoplasms / genetics. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Carcinoembryonic Antigen / analysis. Case-Control Studies. Cell Proliferation. DNA, Viral / analysis. Female. Humans. Immunohistochemistry. In Situ Hybridization. Mosaicism. Neoplasm Invasiveness. Papillomaviridae / genetics. Polymerase Chain Reaction. Polymorphism, Genetic. Predictive Value of Tests. Stromal Cells / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Mol Pathol. 2001 Mar;10(1):24-33 [11277392.001]
  • [Cites] J Pathol. 2003 Dec;201(4):535-43 [14648656.001]
  • [Cites] Mod Pathol. 2004 Aug;17(8):962-72 [15143335.001]
  • [Cites] Am J Obstet Gynecol. 1975 Apr 1;121(7):971-5 [1115185.001]
  • [Cites] Biochim Biophys Acta. 1976 Oct 12;458(3):283-321 [1067873.001]
  • [Cites] Gynecol Oncol. 1980 Oct;10(2):125-33 [7461479.001]
  • [Cites] Pathology. 2008 Jun;40(4):392-5 [18446630.001]
  • [Cites] Am J Hum Genet. 1992 Dec;51(6):1229-39 [1281384.001]
  • [Cites] Mod Pathol. 1998 Jan;11(1):11-8 [9556417.001]
  • [Cites] Virchows Arch. 1998 Apr;432(4):315-22 [9565340.001]
  • [Cites] Int J Gynecol Pathol. 2005 Jul;24(3):296-302 [15968208.001]
  • [Cites] Diagn Cytopathol. 2006 Feb;34(2):119-23 [16511847.001]
  • [Cites] Development. 1987 Feb;99(2):187-96 [3652995.001]
  • (PMID = 20416098.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / AR protein, human; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / DNA, Viral; 0 / Receptors, Androgen
  • [Other-IDs] NLM/ PMC2877003
  •  go-up   go-down


44. Jun JK, Choi KS, Jung KW, Lee HY, Gapstur SM, Park EC, Yoo KY: Effectiveness of an organized cervical cancer screening program in Korea: results from a cohort study. Int J Cancer; 2009 Jan 1;124(1):188-93
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effectiveness of an organized cervical cancer screening program in Korea: results from a cohort study.
  • Although the value of cervical cancer screening is widely acknowledged, the effectiveness of an organized cervical cancer screening program in Korea has never been evaluated.
  • We investigated the associations of the frequency of cervical cancer screening with cervical cancer incidence using data from a large prospective cohort study.
  • In this analysis, 253,472 women without a hysterectomy or previous cancer diagnosis were included.
  • Using the Korean Central Cancer Registry, 248 cases of invasive cervical cancer and 346 cases of carcinoma in situ (CIS) of the cervix were identified.
  • Subjects screened 2 or more times showed a 71% (corrected reduction 60%) and a 66% (corrected reduction 53%) reduced risk of invasive cervical cancer and CIS of the cervix, respectively, as compared with unscreened subjects [relative risk (RR) = 0.29; 95% confidence interval (CI) = 0.20-0.45; RR = 0.34; 95% CI = 0.25-0.46, respectively].
  • Women with a normal or benign pap smear had a statistically significantly lower risk of invasive cervical cancer and CIS of cervix compared with those never screened.
  • In age-stratified analyses, there was a significant reduction in cervical cancer incidence among women aged 30 and over who were screened 2 or more times compared with women never screened.
  • The results of this prospective cohort study show that regular screening of cervical cancer reduces invasive cervical cancer incidence and CIS of the cervix among Korean women.
  • [MeSH-major] Mass Screening / methods. Uterine Cervical Neoplasms / diagnosis. Uterine Cervical Neoplasms / epidemiology
  • [MeSH-minor] Adult. Body Mass Index. Cohort Studies. Early Detection of Cancer. Female. Humans. Korea. Middle Aged. Neoplasm Invasiveness. Papanicolaou Test. Proportional Hazards Models. Risk. Treatment Outcome. Vaginal Smears

  • Genetic Alliance. consumer health - Cervical cancer.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18785204.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


45. Folpe AL, Mentzel T, Lehr HA, Fisher C, Balzer BL, Weiss SW: Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature. Am J Surg Pathol; 2005 Dec;29(12):1558-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature.
  • This family of tumors includes angiomyolipoma (AML), clear cell sugar tumor of the lung (CCST), lymphangioleiomyomatosis (LAM), and very rare tumors in other locations.
  • Sites of involvement included the omentum or mesentery (6 cases), uterus (4 cases), pelvic soft tissues (3 cases), abdominal wall (2 cases), uterine cervix (2 cases), and vagina, retroperitoneum, thigh, falciform ligament, scalp, broad ligament, forearm, shoulder, and neck (1 case each).
  • Recurrence and/or metastasis was strongly associated tumor size > median size (8 cm), mitotic activity greater than 1/50 HPF, and necrosis.
  • We conclude that PEComas of soft tissue and gynecologic origin may be classified as "benign," "of uncertain malignant potential," or "malignant."
  • Small PEComas without any worrisome histologic features are most likely benign.
  • [MeSH-major] Biomarkers, Tumor / analysis. Epithelioid Cells / pathology. Genital Neoplasms, Female / pathology. Neoplasms, Connective and Soft Tissue / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Immunophenotyping. Male. Middle Aged. Mitosis. Neoplasm Metastasis. Neoplasm Recurrence, Local. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome. Tumor Burden

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16327428.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 56
  •  go-up   go-down


46. Dominical VM, Cavellani CL, Rocha LP, Corrêa RR, Pereira Gde A, Teixeira Vde P: Chagas disease and gynecologic neoplasias. Ann Diagn Pathol; 2010 Oct;14(5):337-40
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chagas disease and gynecologic neoplasias.
  • The objective was to determine the occurrence of gynecologic neoplasia (GN) and demographic characteristics in patients with Chagas disease (CD).
  • The most common benign neoplasm was uterine leiomyoma, and malignant, carcinoma of the cervix.
  • [MeSH-major] Carcinoma / pathology. Chagas Disease / pathology. Leiomyoma / pathology. Trypanosoma cruzi. Uterine Cervical Neoplasms / pathology. Uterine Neoplasms / pathology


47. Abiko K, Baba T, Ogawa M, Mikami Y, Koyama T, Mandai M, Konishi I: Minimal deviation mucinous adenocarcinoma ('adenoma malignum') of the uterine corpus. Pathol Int; 2010 Jan;60(1):42-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Minimal deviation mucinous adenocarcinoma ('adenoma malignum') of the uterine corpus.
  • Primary mucinous adenocarcinomas of the uterine corpus are typically low grade and frequently associated with endometrial hyperplasia and/or ordinary endometrioid adenocarcinoma, but may appear as a heterogeneous group of neoplasms.
  • In some areas endometrial glands of adenomyosis were replaced by benign-looking mucinous metaplasia.
  • The uterine cervix showed no abnormalities.
  • HIK1083 and MUC6 immunohistochemistry indicated a gastric phenotype of the tumor, as seen in cases of prototypical minimal deviation adenocarcinoma (MDA) of the cervix.
  • In summary, mucinous endometrial adenocarcinoma rarely shows features similar to MDA of the cervix.
  • This case provokes a discussion on diagnostic and management strategy, and histogenesis of mucinous neoplasm of the endometrium.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Uterine Cervical Neoplasms / pathology. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20055951.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


48. Huszar M, Moldenhauer G, Gschwend V, Ben-Arie A, Altevogt P, Fogel M: Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy. Hum Pathol; 2006 Aug;37(8):1000-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy.
  • Here we carried out an immunohistochemical survey of L1 expression in normal adults and in a broad range of benign and malignant tumors using monoclonal antibody L1-11A and the novel monoclonal antibody L1-14.10.
  • In tumors of the female genital tract, L1 was detected in adenocarcinomas of the cervix and fallopian tubes, in addition to ovarian and endometrial carcinomas.
  • Our results suggest that L1 expression in tumors is not ubiquitous but restricted to certain subtypes and may be a helpful molecular marker for differential diagnosis and target for antibody-based therapy.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Genital Neoplasms, Female / metabolism. Isoantigens / metabolism. Membrane Glycoproteins / metabolism. Receptors, Cell Surface / metabolism
  • [MeSH-minor] Antibodies, Monoclonal / immunology. Cell Line, Tumor. Diagnosis, Differential. Female. Fluorescent Antibody Technique, Direct. GPI-Linked Proteins. Humans. Immunoenzyme Techniques. Male. Neutrophils / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16867862.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CD177 protein, human; 0 / GPI-Linked Proteins; 0 / Isoantigens; 0 / Membrane Glycoproteins; 0 / Receptors, Cell Surface
  •  go-up   go-down


49. Oberg TN, Kipp BR, Vrana JA, Bartholet MK, Fales CJ, Garcia R, McDonald AN, Rosas BL, Henry MR, Clayton AC: Comparison of p16INK4a and ProEx C immunostaining on cervical ThinPrep cytology and biopsy specimens. Diagn Cytopathol; 2010 Aug;38(8):564-72
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of p16INK4a and ProEx C immunostaining on cervical ThinPrep cytology and biopsy specimens.
  • ProEx C and p16(INK4a) staining of cytology/histology specimens have recently been explored to help distinguish high-grade squamous intraepithelial lesions (HSIL) from benign mimics.
  • Residual cervical ThinPrep cytology specimens and tissue blocks (N = 64) from 63 patients were stained with p16 and ProEx C.
  • [MeSH-major] Antibodies, Monoclonal / immunology. Antibodies, Neoplasm / immunology. Antigens, Neoplasm / immunology. Cervix Uteri / pathology. Cyclin-Dependent Kinase Inhibitor p16 / immunology. DNA Topoisomerases, Type II / immunology. DNA-Binding Proteins / immunology. Papanicolaou Test. Staining and Labeling / methods. Vaginal Smears / methods

  • MedlinePlus Health Information. consumer health - Cervical Cancer Screening.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Wiley-Liss, Inc.
  • (PMID = 19937941.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / Coloring Agents; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA-Binding Proteins; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


50. Newsom-Davis T, Poulter D, Gray R, Ameen M, Lindsay I, Papanikolaou K, Butler-Manuel S, Christmas T, Townsend P, Seckl M: Case report: malignant teratoma of the uterine corpus. BMC Cancer; 2009;9:195
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: malignant teratoma of the uterine corpus.
  • Uterine teratomas are extremely rare with only a few previous case reports, usually involving mature teratomas of the uterine cervix.
  • Initial investigations revealed a benign teratoma of the uterus which was removed.
  • Her symptoms persisted and a recurrent, now malignant, teratoma of the uterine corpus was resected at hysterectomy.
  • CONCLUSION: In this report we discuss the aetiology, diagnosis and management of uterine teratomas, and review previous case studies.
  • [MeSH-major] Teratoma / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Hysterectomy. Lymphatic Diseases / etiology. Lymphatic Metastasis. Neoplasm Metastasis. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Int. 2003 May;53(5):327-31 [12713570.001]
  • [Cites] Br J Cancer. 2004 Mar 22;90(6):1169-75 [15026797.001]
  • [Cites] Obstet Gynecol. 1972 Nov;40(5):686-91 [5083218.001]
  • [Cites] N Engl J Med. 1975 Jan 9;292(2):63-6 [162806.001]
  • [Cites] Histopathology. 1979 Jul;3(4):339-45 [468134.001]
  • [Cites] Gynecol Oncol. 1985 May;21(1):106-10 [3988122.001]
  • [Cites] Ann Oncol. 2008 Sep;19(9):1578-83 [18453518.001]
  • [Cites] Acta Obstet Gynecol Scand. 1998 Oct;77(9):936-8 [9808385.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jul;185(1):216-8 [15972426.001]
  • [Cites] Ultrasound Obstet Gynecol. 2007 Apr;29(4):477-8 [17330830.001]
  • [Cites] Ann Diagn Pathol. 2007 Aug;11(4):293-6 [17630116.001]
  • [Cites] Obstet Gynecol. 2007 Aug;110(2 Pt 2):491-3 [17666639.001]
  • [Cites] Int J Gynecol Cancer. 2008 Jan-Feb;18(1):43-50 [17466047.001]
  • [Cites] Kurume Med J. 1993;40(3):153-8 [8139215.001]
  • (PMID = 19538751.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2709639
  •  go-up   go-down


51. Metser U, You J, McSweeney S, Freeman M, Hendler A: Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen. AJR Am J Roentgenol; 2010 Mar;194(3):766-71
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen.
  • OBJECTIVE: The purpose of this study was to compare FDG PET/CT and contrast-enhanced 64-MDCT of the chest, abdomen, and pelvis in the detection of tumor recurrence in patients with colorectal cancer and an elevated level of carcinoembryonic antigen (CEA).
  • MATERIALS AND METHODS: A retrospective analysis included 50 patients (31 men, 19 women; mean age, 61 years; range, 28-89 years) with 55 clinical events of elevated or increasing CEA level who underwent FDG PET/CT and MDCT for suspected tumor recurrence.
  • Fifty-four of 61 tumor sites suspected as tumor recurrence with any imaging technique were found to be local recurrence or metastatic colorectal cancer at final analysis.
  • The other seven sites were one separate malignant tumor (small lymphocytic lymphoma) and six benign lesions.
  • Diagnosis was based on histopathologic findings (n = 27) or clinical and imaging findings (n = 35) during a median follow-up period of 12 months (range, 6-31 months).
  • One site of tumor recurrence was missed prospectively at both MDCT and PET/CT.
  • In a tumor site-based analysis, the sensitivities of PET/CT and MDCT were 98.1% and 66.7% (p < 0.0001), and the specificities were 75% and 62.5% (p = 0.56).
  • Tumors correctly identified with PET/CT and missed with MDCT were local recurrence in the presacral space (n = 5), metastatic subcentimeter lymph nodes (n = 4), peritoneal deposits (n = 3), and recurrences at the periphery of radiofrequency ablated metastatic lesions of the liver (n = 2) and in the abdominal wall (n = 1), liver (n = 1), and uterine cervix (n = 1).
  • [MeSH-major] Colorectal Neoplasms / radiography. Colorectal Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Neoplasm Recurrence, Local / radiography. Neoplasm Recurrence, Local / radionuclide imaging. Radiopharmaceuticals. Tomography, Emission-Computed / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoembryonic Antigen / blood. Contrast Media. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / radiography. Neoplasm Metastasis / radionuclide imaging. Radiographic Image Interpretation, Computer-Assisted. Radiography, Abdominal. Radiography, Thoracic. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20173157.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Contrast Media; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


52. Ko ML, Lin HW, Chen SC, Pan HS: Should cystoscopy be routinely performed after laparoscopy-assisted vaginal hysterectomy? Minim Invasive Ther Allied Technol; 2008;17(3):195-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were eighty patients who underwent LAVH for benign tumors of the uterus (adenomyosis and myoma), uterine prolapse, persistent intraepithelial neoplasm of the cervix (CIN3) and cervical carcinoma in situ (CIS).
  • From among the 80 patients who underwent LAVH, 52 had myoma, 19 had adenomyosis, six patients had uterine prolapse, one had CIS and seven patients were diagnosed to have CIN3.
  • [MeSH-major] Cystoscopy / methods. Hysterectomy, Vaginal / adverse effects. Intraoperative Complications / diagnosis. Laparoscopy / adverse effects
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Hematuria / etiology. Humans. Middle Aged. Postoperative Complications / prevention & control. Retrospective Studies. Stents. Ureter / injuries. Ureter / surgery. Ureteral Obstruction / diagnosis. Ureteral Obstruction / etiology. Ureteral Obstruction / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18608998.001).
  • [ISSN] 1365-2931
  • [Journal-full-title] Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  • [ISO-abbreviation] Minim Invasive Ther Allied Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down






Advertisement